The Potential for an Interaction between MRP2 (ABCC2) and Various Therapeutic Agents: Probenecid as a Candidate Inhibitor of the Biliary Excretion of Irinotecan Metabolites

Drug Metabolism and Pharmacokinetics

Volumn 17, Issue 1, 2002, Pages 23-33

  Horikawa, Masato ^a   Kato, Yukio ^a   Sugiyama, Yuichi ^a   Tyson, Charles A ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b SRI INTERNATIONAL   (United States)

Author keywords

biliary excretion; CPT 11; MRP2; probenecid; SN 38

Indexed keywords

EID: 0037613131     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.17.23     Document Type: Article

References (50)

1. Takasuna, K., Kasai, Y., Kitano, Y., Mori, K., Kakihata, K., Hirohashi, M. and Nomura, M.: Study on the mechanisms of diarrhea induced by a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats. Folia Pharmacol. Jpn., 105: 447-460 (1995).
2. Ahmed, F., Vyas, V., Cornfield, A., Goodin, S., Ravikumar, T. S., Rubin, E. and Gupta, E.: In vitro activation of irinotecan to SN-38 by human liver and intestine. Anticancer Res., 19: 2067-2072 (1999).
3. Kaneda, N. and Yokokura, T.: Nonlinear pharmacokinetics of CTP-11 in rats. Cancer Res., 50: 1715-1725 (1990).
4. Lokiec, F., Canal, P., Gay, C., Chatelut, E., Armand, J.-P., Roche, H., Bugat, R., Goncalves, E. and Mathieu-Boue, A.: Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urine. Cancer Chemother. Pharmacol., 36: 79-82 (1995).
5. Gupta, E., Lestingi, T. M., Mick, R., Ramirez, J., Vokes, E. E. and Ratain, M. J.: Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea. Cancer Res., 54: 3723-3725 (1994).
6. Takasuna, K., Kasai, Y., Kitano, Y., Mori, K., Kobayashi, R., Hagiwara, T., Kakihata, K., Hirohashi, M., Nomura, M., Nagai, E. and Kamataki, T.: Prospective effect of Kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats. Jpn. J. Cancer Res., 86: 978-984 (1995).
7. Chu, X.-Y., Kato, Y. and Sugiyama, Y.: Multiplicity of biliary excretion mechanisms of irinotecan, CPT-11, and its metabolites in rats. Cancer Res., 57: 1934-1938 (1997).
8. Chu, X.-Y., Kato, Y., Niinuma, K., Sudo, K., Hakusui, H. and Sugiyama, Y.: Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats. J. Pharmacol. Exp. Ther., 281: 304-314 (1997).
9. Chu, X.-Y., Suzuki, H., Ueda, K., Kato, Y., Akiyama, S. and Sugiyama, Y.: Active efflux of CPT-11 and its metabolites in human KB-derived cell lines. J, Pharmacol. Exp. Ther., 288: 735-741 (1999).
10. Saxena, M. and Henderson, G. B.: ATP-dependent efflux of 2,4-dinitrophenyl-S-glutathione. J. Biol. Chem., 270: 5312-5319 (1995).
11. Chu, X.-Y., Kato, Y., Ueda, K., Suzuki, H., Niinuma, K., Tyson, C. A., Weizer, V., Dabbs, J. E., Froehlich R., Green, C. A. and Sugiyama, Y.: Biliary excretion mechanism of CPT-11 and its metabolites in humans: Involvement of primary active transporters Cancer Res., 58: 5137-5143 (1998).
12. Horikawa, M., Kato, Y. and Sugiyama, Y.: Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats. Pharm. Res., submitted (2001).
13. Peterson, L. R.: Quantitative binding of penicillin G to tissue homogenates as determined with the preparative ultracentrifuge. J. Lab. Clin. Med., 91: 463-466 (1978).
14. Niinuma, K., Kato, Y., Suzuki, H., Tyson, C. A., Weizer, V., Dabbs, J. E., Froehlich, R., Green, C. E. and Sugiyama, Y.: Primary active transport of organic anions on bile canalicular membrane in humans. Am. J. Physiol., 276: G1153-G1164 (1999).
15. Yamaoka, Y., Tanigawara, Y., Nakagawa, Y. and Uno, T.: A pharmacokinetic analysis program (MULTI) for microcomputer. J. Pharmacobio.-Dyn., 4: 879-885 (1981).
16. Ito, K., Iwatubo, T., Kanamitsu, S., Ueda, K., Sizuki, H. and Sugiyama, Y.: Prediction of pharmacokinetic alterations caused by drug-drug interactions: Meabolic interaction in the liver. Pharmacol. Rev., 50: 387-411 (1998).
17. Gupta, E., Ahmad, R. S., Wang, X. and Ratain, M. J.: Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A. Cancer Res., 56: 1309-1314 (1996).
18. Sasaki, Y., Ohtsu, A., Shimada, Y., Ono, K. and Saijyo, N.: Simultaneous administration of CPT-11 and fluorouracil: Alteration of the pharmacokinetics of CPT-11 and SN-38 in patients with advanced colorectal cancer. J. Natl. Cancer Inst., 86: 101-110 (1994).
19. Adjei, A. A., Klein, C. E., Kastrissios, H., Goldberg, R. M., Alberts, S. R., Pitot, H. C., Sloan, J. A., Reid, J. M., Hanson, L. J., Atherton, P., Rubin, J. and Erlichman, C.: Phase I and pharmacokinetics study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity. J. Clin. Oncol., 18: 1116-1123 (2000).
20. Akutsu, M., Suzuki, K., Tsunoda, S., Kano, Y. and Miura, Y.: Effects of SN-38 in combination with other anticancer agents against Dauji cells. Gan To Kagaku Ryoho, 21: 1607-1611 (1994).
21. Bohme, M., Buchler, M., Muller, M. and Keppler, D.: Differential inhibition by cyclosporins of primary-active ATP-dependent transporters in the hepatocyte canalicular membrane. FEBS Lett., 333: 193-196 (1994).
22. Sathirakul, K., Suzuki, H., Yamada, T., Hanano, M. and Sugiyama, Y.: Multiple transport systems for organic anions across the bile canalicular membranes. J. Pharm. Exp. Ther., 268: 65-73 (1994).
23. Emanuelsson, B.-M., Beermann, B. and Paalzow, L. K.: Nonlinear elimination and protein binding of probenecid. Eur. J. Clin. Pharmacol., 32: 395-401 (1987).
24. Hacki, W., Bricher, J. and Preisig, R.: A new look at the plasma disappearance of sulfobromophthalein (BSP): Correlation with the BSP transport maximum and the hepatic plasma flow in man. J. Lab. Clin. Med., 88: 1019-1031 (1976).
25. Scholtan, V. W. and Gloxhuber, C.: Protein binding of bilirubin and bromosulfalein. Arzneimittelforschung, 16: 520-528 (1968).
26. Yamamura, Y., Kawakami, J., Santa, T., Kataki, H., Uchino, K., Sawada, Y., Tanaka, N. and Iga, T.: Pharmacokinetic profile of glycyrrhizin in healthy volunteers by a new high-performance liquid chromatographic method. J. Pharm. Sci., 81: 1042-1046 (1992).
27. Sekimoto, M., Fukui, M. and Fujita, K.: Plasma volume estimation using indocyanine green with biexponential regression analysis of the decay curves. Anaesthesia, 52: 1166-1172 (1997).
28. Kobayashi, N.: Binding of indocyanine green (ICG) to normal human serum protein. Nipponsyokakibyogak-kaizasshi, 75: 306-314 (1978).
29. Matsusita, H., Suzuki, H., Sugiyama, Y., Sawada, Y., Iga, T. and Hanano, M.: Prediction of the Pharmacokinetics of Cefodizime and Cefotetan in Humans from Pharmacokinetic Parameters in Animals. J. Pharmacobio.-Dyn., 13: 602-611 (1990).
30. Hardman, J. G., Limbird, L. E., Molinoff, P. B. and Rudden, R. W.: Goodman & Gilman's The Pharmacological basis of Therapeutics, 9th ed., McGraw-Hill, Health Professions, New York, 1996, pp. 1715-1773.
31. Nash, J. F., Bechtol, L. D., Bunde, C. A., Bopp, R. J., Farid, K. Z. and Spradlin, C. T.: Linear pharmacokinetics of orally administered fenoprofen calcium. J. Pharm. Sci., 68: 1087-1090 (1979).
32. Verbeeck, R. K., Blackburn, J. L. and Loewen, G. R.: Clinical pharmacokinetics of non-steroidal anti-inflammatory drugs. Clin. Pharmacokinet., 8: 279-331 (1983).
33. Hyneck, M. L., Smith, P. C., Munafo, A., McDonagh, A. F. and Benet, L. Z.: Disposition and irreversible plasma protein binding of tolmetin in humans. Clin. Pharmacol. Ther., 44: 107-114 (1988).
34. Kolb, R., Jaschekl, Piza F., Thetter, O. and Tizian, C. H.: Concentration course of Na-penicillin G in wound secretions following vascular surgery. Int. J. Clin. Pharmacol. Biopharm., 13: 127-132 (1976).
35. Kunin, C. M. and Va, C.: Clinical pharmacology of the new penicillins-I The importance of serum protein binding in determining antimicrobial activity and concentration in serum. Clin. Pharmacol. Ther., 7: 166-179 (1967).
36. McGuire, B. W., Sia, L. L., Leese, P. T., Gutierrez, M. L. and Stokstad E. L. R.: Pharmacokinetics of leucovo-rin calcium after intravenous, intramuscular, and oral administration. J. Pharm. Sci., 7: 52-58 (1988).
37. Fahr, A.: Cyclosporin clinical pharmacokinetics. Clin. Pharmacokinet., 24: 472-495 (1993).
38. Diasio, R. B. and Harris, B. E.: Clinical pharmacology of 5-fluorouracil. Clin. Pharmacokinet., 16: 215-237 (1989).
39. Celio, L. A., DiGregorio, G. J., Ruch, E., Pace, J. and Piraino, A. J.: Doxorubicin and 5-fluorouracil plasma concentrations and detectability in parotid saliva. Eur. J. Clin. Pharmacol., 24: 261-266 (1983).
40. Sonnichsen, D. S. and Relling, M. V.: Clinical Pharmacokinetics of paclitaxel. Clin. Pharmacokinet., 27: 256-269 (1994).
41. DeAngelis, L. M., Kreith, W., Chan, K., Dantis, E. and Akerman, S.: Pharmacokinetics of ara-C and ara-U in plasma and CSF after high-dose administration of cytosine arabinoside. Cancer Chem. Ther., 29: 173-177 (1992).
42. Slevin, M. L., Johnston, A., Woolard, R. C., Piall, E. M., Lister, T. A. and Turner, P.: Relationship between protein binding and extravascular drug concentrations of a water-soluble drug, cytarabine arabinoside. J. R. Soc. Med., 76: 365-368 (1983).
43. Brocks, D. R., Upward, J., Davy, M., Howland, K., Compton, C., McHugh, C. and Dennis, M. J.: Evening dosing is associated with higher plasma concentrations of pranlukast, a leukotriene receptor antagonist, in healthy male volunteers. Br. J. Clin. Pharmacol., 44: 289-291 (1997).
44. Ishido, M., Shibakawa, K., Takamoto, M., Kajiwara, I., Sawada, M. and Aishita, H.: Studies on the metabolic fate of leukotriene antagonist 0N0-1078 (4): Metabolism and protein binding. Xenobio. Metab. Dispos., 8: 49-66 (1993).
45. Sparreboom, A., Verweij, J., Burg, M. E. L. van der Loos, W. J., Brouwer, E., Vigano, L., Locatelli, A., Vos, A. I. De, Nooter, K., Stoter, G. and Gianni, L.: Disposition of cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo. Clin. Cancer. Res., 4: 1937-1942 (1998).
46. Takahashi, M., Onoue, M., Kaneko, K., Kobayashi, T., Chiba, K., Tohyama, K. and Fujiwara, H.: Intravenous chronic toxicity study of CPT-11 in rats. Clin. Rep., 24: 55-82 (1990).
47. Ueda, K., Kato, Y., Komatsu, K. and Sugiyama, Y.: Inhibition of biliary excretion of methotrexate by probenecid in rats: Quantitative prediction of interaction from in vitro data. J. Pharm. Exp. Ther., 297: 1036-1043 (2001).
48. Li, L., Meier, P. J. and Ballatori, N.: 0atp2 mediates bidirectional organic solute transport: a role for intracellular glutathione. Mol. Pharmacol., 58: 335-340 (2000).
49. van Montfoort, J. E., Stieger, B., Meijer, D. K., Weinmann, H. J., Meier, P. J. and Fattinger, K. E.: Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide 0atp1. J. Pharmacol. Exp. Ther., 290: 153-157 (1999).
50. Gupta, E., Wang, X., Ramirez, J. and Ratain, M. J.: Modulation of glucuronidation of SN-38, The active metabolite of irinotecan, by valpronic acid and phenobarbital. Cancer Chemother. Pharmacol., 39: 440-444 (1997).